Another group treated metastatic HER2-positive bladder and BC patients with DCs transduced with an adenoviral vector expressing different HER2 domains, demonstrating clinical benefits in up to one third of the patients, together with immune responses [55]. The gene discussed is ERBB2; the disease is breast cancer.